BlackRock Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$7K	Hold	282	–	–	﹤0.01%	3604
2016 Q3	$11K	Hold	282	–	–	﹤0.01%	3560
2016 Q2	$15K	Hold	282	–	–	﹤0.01%	3503
2016 Q1	$17K	Hold	282	–	–	﹤0.01%	3461
2015 Q4	$27K	Hold	282	–	–	﹤0.01%	3396
2015 Q3	$15K	Buy	282 +97	+52%	+$6.48K	﹤0.01%	3576
2015 Q2	$15K	Sell	185 -328	-64%	-$28K	﹤0.01%	3557
2015 Q1	$38K	Sell	513 -1,188	-70%	-$141K	﹤0.01%	3307
2014 Q4	$301K	Buy	1,701 +72	+4%	+$13.7K	﹤0.01%	2358
2014 Q3	$327K	Buy	1,629 +299	+22%	+$59.3K	﹤0.01%	2293
2014 Q2	$288K	Buy	+1,330	New	+$443K	﹤0.01%	2407

Other funds holding ATNM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's ATNM Position: Q4 2016 in Review

BlackRock Advisors held its Actinium Pharmaceuticals (ATNM) position steady in Q4 2016 at 282 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #3604.

BlackRock Advisors first reported a position in ATNM in Q2 2014 and has held it in 11 quarters since. The position peaked at $327K in Q3 2014. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

BlackRock Advisors held 282 shares of Actinium Pharmaceuticals worth $7K as of Q4 2016.
BlackRock Advisors left its Actinium Pharmaceuticals share count unchanged in Q4 2016.
Actinium Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3604 holding.
BlackRock Advisors first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
BlackRock Advisors's Actinium Pharmaceuticals position peaked at $327K in Q3 2014.
30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.